BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

Myriad Genetics has a 12-month low of $7.35 and a 12-month high of $29.30. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05.

The "Genetic Screening Testing for Reproductive Health Market - A Global and Regional Analysis: Focus on Test Type, Application, Technology, End User, and Country-Level Analysis - Analysis and ...

Guggenheim downgraded Myriad Genetics (MYGN) to Neutral from Buy without a price target Based on key opinion leader checks on GeneSight and ...

The direct-to-consumer (DTC) genetic testing market is projected to grow at a CAGR of ~12% over the forecast period. Major ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on NeoGenomics ( NEO – Research Report ), with a price target of $18.00. The company’s shares closed last Friday ...

Detailed price information for Akoya Biosciences Inc (AKYA-Q) from The Globe and Mail including charting and trades.

Piper Sandler analyst David Westenberg maintained a Buy rating on Illumina (ILMN – Research Report) today and set a price target of $190.00.

The global Breast Cancer Diagnostics Market is valued at USD 19.43 Billion in 2024 and is projected to reach a value of USD ...

Entrepreneurial CMO 50 list recognizes fifty chief marketers whose approach to driving growth is charting new paths.